The goal of this observational study is to learn whether intravenous iloprost treatment for severe frostbite (grades 3-4) is feasible and safe when delivered in pre-hospital, remote high-altitude settings. The main questions it aims to answer are: * Is it feasible to initiate and deliver guideline-based intravenous iloprost for grade 3-4 frostbite at high altitude and what logistical barriers arise? * Does field-based initiation of iloprost increase tissue preservation and reduce amputations (compared to historical cases from similar settings)? Participants receiving Iloprost as part of a frostbite treatment will be followed up after discharge as well as 6, 12 and 18 months to assess tissue preservation and long-term sequelae from the initial frostbite injury.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Proportion of frostbite presentations with severe frostbite (Grade 3-4) at Everest ER
Timeframe: from enrolment to the end of treatment at 1 week
Proportion of eligible severe frostbite patients who complete ≥1 field iloprost treatment round
Timeframe: From enrolment to 1 week after beginning of treatment
Time from thawing to initiation of iloprost treatment under field conditions
Timeframe: From enrolment to the end of treatment at day 1
Proportion of iloprost-treated patients with mild adverse effects during/after ≥1 treatment round in the field setting
Timeframe: From enrollment to the end of treatment at 1 week
Proportion of iloprost-treated patients with severe adverse effects during/after ≥1 treatment round in the field
Timeframe: From enrolment to the end of treatment at 1 week
Proportion of patients discontinuing field iloprost treatment (overall) and documented reasons for discontinuation
Timeframe: From enrolment to end of treatment at 1 week
Proportion of iloprost treatment discontinuations attributable to adverse effects in the field
Timeframe: From enrolment to end of treatment at 1 week
Qualitative description of logistical constraints and solutions from field notes and staff reports
Timeframe: From enrolment to end of treatment at 1 week
Frequency of logistical challenges during field iloprost implementation
Timeframe: from enrolment to end of treatment at 1 week
Proportion of logistical challenges resolved during the study period
Timeframe: from enrolment to end of treatment at week 1
Mean (SD) time from thawing to first iloprost administration (clinical charts/notes), stratified by logistical challenge status (none vs occurred), resolution status (resolved vs unresolved), and challenge category
Timeframe: From enrolment to end of treatment at 1 week